This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Caremark says confidential information at risk in US FTC's insulin suit

( October 22, 2024, 21:31 GMT | Official Statement) -- MLex Summary: Caremark Rx told a US Federal Trade Commission administrative law judge that it will be prejudiced by the "significant time and expense" associated with protecting its confidential information from competing pharmacy benefit management companies Optum Rx and Express Scripts, who face FTC claims that they have inflated insulin prices through anticompetitive rebate schemes. "Because Respondents are competitors, a joint hearing will introduce significant challenges associated with protecting each Respondent’s confidential information," Caremark said in a motion for a separate evidentiary hearing filed in the FTC's administrative court. See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections